112 related articles for article (PubMed ID: 15075363)
1. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis.
Ruffini PA; Biragyn A; Coscia M; Harvey LK; Cha SC; Bogen B; Kwak LW
J Leukoc Biol; 2004 Jul; 76(1):77-85. PubMed ID: 15075363
[TBL] [Abstract][Full Text] [Related]
2. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.
Biragyn A; Tani K; Grimm MC; Weeks S; Kwak LW
Nat Biotechnol; 1999 Mar; 17(3):253-8. PubMed ID: 10096292
[TBL] [Abstract][Full Text] [Related]
3. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21.
Yamano T; Kaneda Y; Hiramatsu SH; Huang S; Tran AN; Giuliano AE; Hoon DS
Cancer Gene Ther; 2007 May; 14(5):451-9. PubMed ID: 17318199
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells.
Fredriksen AB; Sandlie I; Bogen B
Mol Ther; 2006 Apr; 13(4):776-85. PubMed ID: 16414309
[TBL] [Abstract][Full Text] [Related]
5. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity.
Crittenden M; Gough M; Harrington K; Olivier K; Thompson J; Vile RG
Cancer Res; 2003 Sep; 63(17):5505-12. PubMed ID: 14500387
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
7. Expression of the chemokine antagonist vMIP II using a non-viral vector can prolong corneal allograft survival.
Pillai RG; Beutelspacher SC; Larkin DF; George AJ
Transplantation; 2008 Jun; 85(11):1640-7. PubMed ID: 18551072
[TBL] [Abstract][Full Text] [Related]
8. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
Pai Kasturi S; Qin H; Thomson KS; El-Bereir S; Cha SC; Neelapu S; Kwak LW; Roy K
J Control Release; 2006 Jul; 113(3):261-70. PubMed ID: 16793161
[TBL] [Abstract][Full Text] [Related]
10. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
11. Chemokine receptor-mediated delivery of mycobacterial MPT51 protein efficiently induces antigen-specific T-cell responses.
Uchijima M; Nagata T; Koide Y
Vaccine; 2008 Sep; 26(40):5165-9. PubMed ID: 18456373
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
13. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines.
Hauser H; Shen L; Gu QL; Krueger S; Chen SY
Gene Ther; 2004 Jun; 11(11):924-32. PubMed ID: 15085173
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.
Huleatt JW; Jacobs AR; Tang J; Desai P; Kopp EB; Huang Y; Song L; Nakaar V; Powell TJ
Vaccine; 2007 Jan; 25(4):763-75. PubMed ID: 16968658
[TBL] [Abstract][Full Text] [Related]
16. MC148 encoded by human molluscum contagiosum poxvirus is an antagonist for human but not murine CCR8.
Lüttichau HR; Gerstoft J; Schwartz TW
J Leukoc Biol; 2001 Aug; 70(2):277-82. PubMed ID: 11493620
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity.
Biragyn A; Schiavo R; Olkhanud P; Sumitomo K; King A; McCain M; Indig FE; Almanzar G; Baatar D
J Immunol; 2007 Jul; 179(2):1381-8. PubMed ID: 17617631
[TBL] [Abstract][Full Text] [Related]
18. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions.
Biragyn A; Kwak LW
Immunol Rev; 1999 Aug; 170():115-26. PubMed ID: 10566146
[TBL] [Abstract][Full Text] [Related]
19. Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression.
Fong CL; Mok CL; Hui KM
Gene Ther; 2006 Feb; 13(3):245-56. PubMed ID: 16163376
[TBL] [Abstract][Full Text] [Related]
20. Viral vectors for gene transfer into antigen presenting cells.
Monahan SJ; Salgaller ML
Curr Opin Mol Ther; 1999 Oct; 1(5):558-64. PubMed ID: 11249662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
